Espinosa BJ, Rentería CJC, Alejo GJA

Idioma: Español
Referencias bibliográficas: 35
Paginas: 8-15
Archivo PDF: 362.80 Kb.

RESUMEN

Antecedentes: Actualmente se utiliza ampliamente la combinación de finasteride y dutasteride por vía oral y la aplicación de minoxidil por vía tópica para el tratamiento de la alopecia androgenética. Sin embargo, pocos estudios –a excepción de los llevados a cabo en modelos animales– han mostrado la efectividad y seguridad de la combinación de varios tratamientos. En este estudio se evaluó la eficacia y seguridad de la aplicación de minoxidil por vía tópica y el régimen oral de finasteride y dutasteride durante un periodo de 65 semanas. Métodos: Este es un ensayo clínico no aleatorizado, sin cegamiento; la evaluación fue realizada por el médico tratante en cada consulta, auxiliándose de la inspección de fotografías secuenciales. Así mismo, se realizó un análisis de las imágenes digitalizadas al término del estudio por medio de la comparación de sus histogramas. Resultados: Mediante el análisis llevado a cabo, se identificaron únicamente 3 (6.8%) pacientes cuyos cambios no fueron significativos. Respecto a la seguridad de los tratamientos utilizados durante este estudio, solamente un paciente reportó problemas de disfunción sexual, a quien se le indicó una determinación de antígeno prostático. Conclusiones: Los resultados obtenidos sugieren que la combinación del tratamiento tópico y el régimen oral promueve el crecimiento de cabello nuevo. Así mismo, la evaluación de la eficacia mediante el análisis de las imágenes digitalizadas proporcionó datos cuantitativos que permitieron comparar diferentes grupos de pacientes, sin encontrar diferencias estadísticamente significativas entre ellos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1.Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clinic Proceedings. 2005; 80: 1316-1322.

2. 2.Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Reviews in Molecular Medicine. 2002; 4: 1-11.

3. 3.Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999; 341: 491-497.

4. 4.Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5 and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999; 41: 717-721.

5. 5.Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974; 186: 1213-1215.

6. 6.Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999; 41: 550-554.

7. 7.Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997; 109: 296-300.

8. 8.Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001; 144: 297-304.

9. 9.Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001; 19: 167-78.

10. 10.Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences. 1951; 53: 708-728.

11. 11.Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001; 45: S70-80.

12. 12.Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97: 247-254.

13. 13.Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001; 7: 293-301.

14. 14.Whiting D. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993; 28: 755-763.

15. 15.Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG et al. A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004; 50: 541-553.

16. 16.Whiting DA, Waldstreicher J. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999; 4: 282-284.

17. 17.Bunagan MJKS. Medical treatment of hair loss. In: Pathomvanich D, Imagawa K et al. Hair restoration surgery in Asians. 1st ed. Springer; 2010. pp. 65-69.

18. 18.Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010; 63: 252-258.

19. 19.Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010; 146: 1141-1150.

20. 20.Otberg, N, Restrepo I, Shapiro R. Possibilities and limitations for reversal of age-related hair loss. In: Trüeb RM, Tobin DJ et al. Aging hair. Berlin: Springer; 2010. pp. 193-205.

21. 21.Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006; 55: 71-74.

22. 22.Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of longitudinal data. 2nd ed. USA: Oxford University Press; 2002.

23. 23.Norwood O. Male pattern baldness: classification and incidence. South Med J. 1975; 68: 1359-1365.

24. 24.Gibbons RD, Fiedler-Weiss VC, West DP, Lapin G. Quantification of scalp hair –a computer aided methodology. J Invest Dermatol. 1986; 86: 78-82.

25. 25.Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996; 14: 713-721.

26. 26.Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. New York: McGraw Hill; 1988.

27. 27.Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. 1979; 101: 593-595.

28. 28.Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980; 303: 1480-1481.

29. 29.Han JH, Kwon OS, Chung JH, Cho KH, Eun HC, Kim KH. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci. 2004; 34: 91-98.

30. 30.Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004; 150: 186-194.

31. 31.Kaufman K. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin. 1996; 14: 697-711.

32. 32.Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004; 63: 709-715.

33. 33.Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006; 55: 1014-1023.

34. 34.Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab. 1992; 74: 345-350.

35. 35.Hoffmann R. TrichoScan: a novel tool for the analysis of hair growth in vivo. J Investig Dermatol Symp Proc. 2003; 8 (1): 109-115.